Literature DB >> 17262024

Fanconi anemia and breast cancer susceptibility.

Ketan J Patel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17262024     DOI： 10.1038/ng0207-142

Source DB:  PubMed          Journal:  Nat Genet        ISSN： 1061-4036            Impact factor:   38.330


× No keyword cloud information.
  10 in total

1.  FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway.

Authors:  Chen Ling; Masamichi Ishiai; Abdullah Mahmood Ali; Annette L Medhurst; Kornelia Neveling; Reinhard Kalb; Zhijiang Yan; Yutong Xue; Anneke B Oostra; Arleen D Auerbach; Maureen E Hoatlin; Detlev Schindler; Hans Joenje; Johan P de Winter; Minoru Takata; Amom Ruhikanta Meetei; Weidong Wang
Journal:  EMBO J       Date:  2007-03-29       Impact factor: 11.598

2.  Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

Authors:  Malcolm A Smith; Oliver A Hampton; C Patrick Reynolds; Min H Kang; John M Maris; Richard Gorlick; E Anders Kolb; Richard Lock; Hernan Carol; Stephen T Keir; Jianrong Wu; Raushan T Kurmasheva; David A Wheeler; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2014-09-27       Impact factor: 3.167

3.  Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer.

Authors:  Philip S Rudland; Angela M Platt-Higgins; Lowri M Davies; Suzete de Silva Rudland; James B Wilson; Abdulaziz Aladwani; John H R Winstanley; Dong L Barraclough; Roger Barraclough; Christopher R West; Nigel J Jones
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

4.  Fanconi anemia and breast cancer susceptibility meet again.

Authors:  Ephrat Levy-Lahad
Journal:  Nat Genet       Date:  2010-05       Impact factor: 38.330

Review 5.  RAD51C: a novel cancer susceptibility gene is linked to Fanconi anemia and breast cancer.

Authors:  Kumar Somyajit; Shreelakshmi Subramanya; Ganesh Nagaraju
Journal:  Carcinogenesis       Date:  2010-10-15       Impact factor: 4.944

Review 6.  Hereditary breast cancer: new genetic developments, new therapeutic avenues.

Authors:  Philippe M Campeau; William D Foulkes; Marc D Tischkowitz
Journal:  Hum Genet       Date:  2008-06-25       Impact factor: 4.132

7.  Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer.

Authors:  Susan M Domchek; Jiangbo Tang; Jill Stopfer; Dana R Lilli; Nancy Hamel; Marc Tischkowitz; Alvaro N A Monteiro; Troy E Messick; Jacquelyn Powers; Alexandria Yonker; Fergus J Couch; David E Goldgar; H Rosemarie Davidson; Katherine L Nathanson; William D Foulkes; Roger A Greenberg
Journal:  Cancer Discov       Date:  2012-12-26       Impact factor: 39.397

8.  Biomarkers and mechanisms of FANCD2 function.

Authors:  Henning Willers; Lisa A Kachnic; Chen-Mei Luo; Li Li; Martin Purschke; Kerstin Borgmann; Kathryn D Held; Simon N Powell
Journal:  J Biomed Biotechnol       Date:  2008

9.  Cancer incidence in relatives of British Fanconi Anaemia patients.

Authors:  Marc Tischkowitz; Douglas F Easton; Jan Ball; Shirley V Hodgson; Christopher G Mathew
Journal:  BMC Cancer       Date:  2008-09-11       Impact factor: 4.430

Review 10.  The biological effects and clinical implications of BRCA mutations: where do we go from here?

Authors:  Dominique Stoppa-Lyonnet
Journal:  Eur J Hum Genet       Date:  2016-09       Impact factor: 4.246
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.